Who founded Correlia Biosystems?

Correlia Biosystems was founded by Akwasi Apori, Kursad Araz, Samuel Tia.

Who are Correlia Biosystems's investors?

Correlia Biosystems's investors include Beresford Ventures, Blue Bear Ventures, Cota Capital, Endurance28, Pallasite Ventures, Pangaea Ventures Us Inc., SV Latam Capital, Y Combinator and 12 more.

How much funding has Correlia Biosystems raised?

Correlia Biosystems has disclosed $10.8M raised across 2 rounds.

Where is Correlia Biosystems headquartered?

Correlia Biosystems is headquartered in San Francisco, US.

Correlia Biosystems

DefunctYC W18

San Francisco, US · Delaware corporation · 16 employees · 20 known investors

Find your way into Correlia Biosystems

Paths you didn't know you had: your email and LinkedIn already hold routes to the Correlia Biosystems team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Correlia Biosystems, a UC Berkeley spinoff, develops microscale tools for rapid quantification of biomolecules from microliter-scale blood samples, aimed at generating large proteomic data sets for pharmaceutical companies. Its applications span next-generation proteomics research and point-of-care diagnostics.

Biotech Deep Tech Hardware Healthtech Medical Devices Lab-on-a-chip MicrofluidicsUnited States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (W18)

Akwasi AporiCo-founder

Kursad ArazCo-Founder & CTO2013–2025Kursad Araz is founder and CTO of Correlia Biosystems, where he leads development of the PIXI platform for automated protein quantification. His background spans hardware and software product development, with experience across R&D, assay design, and team leadership in laboratory instrumentation.

Samuel TiaFounder2013–2025Samuel Tia is a bioengineer with experience in product development, scale-up, and manufacturing. He has worked with customers on biotechnology applications and has built and managed product R&D and manufacturing teams.

Investors · 20

Beresford Ventureslisted by Beresford VenturesOrlando

Blue Bear Ventureslisted by Blue Bear VenturesBerkeley · $100K – $400K

How we know: Blue Bear Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Cota Capitallisted by Cota CapitalSan Francisco

How we know: Cota Capital's portfolio page · press coverage · Y Combinator's founder network · Not right? Tell us

Endurance28listed by Endurance28San Francisco

How we know: Endurance28's portfolio page · Y Combinator's founder network · Not right? Tell us

Pallasite Ventureslisted by Pallasite VenturesVancouver · $100K – $1.5M

How we know: Y Combinator's founder network · Not right? Tell us

Pangaea Ventures Us Inc.listed by Pangaea Ventures Us Inc.Vancouver · $500K – $1.5M

How we know: Pangaea Ventures Us Inc.'s portfolio page · the VCSheet dataset · Y Combinator's founder network · Not right? Tell us

SV Latam Capitallisted by SV Latam CapitalSan Francisco · $50K – $500K

How we know: SV Latam Capital's portfolio page · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Alpha PartnersreportedNew York · $3M – $10M

How we know: Y Combinator's founder network · Not right? Tell us

AlphaV VenturesreportedBergamo · $44K – $66K

How we know: Y Combinator's founder network · Not right? Tell us

Baidureported

How we know: Y Combinator's founder network · Not right? Tell us

Baidu VenturesreportedBeijing

How we know: Y Combinator's founder network · Not right? Tell us

Cowin Capital GroupreportedShenzhen

How we know: Y Combinator's founder network · Not right? Tell us

Cypher CapitalreportedZurich

How we know: Y Combinator's founder network · Not right? Tell us

LVX VenturesreportedBangalore

How we know: Y Combinator's founder network · Not right? Tell us

Neotribe VenturesreportedMenlo Park · $250K – $2M

How we know: press coverage · Y Combinator's founder network · Not right? Tell us

Probitas CapitalreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

ScienceVestreportedNew York · $125K

How we know: Y Combinator's founder network · Not right? Tell us

The Regents of the University of Californiareported

How we know: press coverage · Y Combinator's founder network · Not right? Tell us

Threshold ImpactreportedKelowna

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$10.8M disclosed across 2 rounds · 2020–2023

▶$1.3MraisedMay 2023 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kittu KolluriDirector
Kursad ArazDirector
Akwasi AporiExecutive Officer, Director

Offering amount: $3.3M
Amount sold: $1.3M
First sale: May 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9.6MraisedOct 2020 · 41 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Akwasi AporiExecutive Officer, Director
Samuel TiaDirector

Offering amount: $9.6M
Amount sold: $9.6M
First sale: Oct 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Indee LabsIndee Labs develops a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to deliver nucleic acids, proteins, and gene editing complexes into patient and donor T cells. The technology targets T cell immunotherapy discovery, development, and manufacturing.

Antlia Bioscience, Inc.Antlia Bioscience develops long-acting therapeutics aimed at treating chronic cardiometabolic diseases.

PreDxion BioPreDxion Bio develops a rapid saliva-based antigen test for detecting SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients, scalable using semiconductor fabrication processes. Its original technology, spun out of the University of Michigan, is a near real-time cytokine and biomarker detection platform for monitoring immune response in critically ill patients, including those undergoing CAR-T therapy.

Intellia TherapeuticsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

Persist AIPersist AI provides AI-driven formulation development services for pharmaceutical compounds, combining robotic lab automation with machine learning models to accelerate drug formulation optimization and reduce time-to-market.

IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Astek DiagnosticsAstek Diagnostics develops a diagnostic platform for rapid and accurate detection of urinary tract infections and related conditions in clinical specimens. The company serves physicians and patients needing point-of-care diagnostic solutions for infectious diseases.

Ancilia BioAncilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).

camferCamfer is an AI-powered CAD tool designed to enhance SolidWorks workflows by enabling users to create designs through text and image descriptions and to query design information without manual navigation.

Companies working in the same space as Correlia Biosystems.

Legal entities · 1

corporate structure

Correlia Biosystems, Inc

In the news

Correlia Biosystems Closes $7M Series A to Enable Product Launchprnewswire.com · Nov 2020

Frequently asked questions

What does Correlia Biosystems do?: Correlia Biosystems, a UC Berkeley spinoff, develops microscale tools for rapid quantification of biomolecules from microliter-scale blood samples, aimed at generating large proteomic data sets for pharmaceutical companies. Its applications span next-generation proteomics research and point-of-care diagnostics.
Who founded Correlia Biosystems?: Correlia Biosystems was founded by Akwasi Apori, Kursad Araz, Samuel Tia.
Who are Correlia Biosystems's investors?: Correlia Biosystems's investors include Beresford Ventures, Blue Bear Ventures, Cota Capital, Endurance28, Pallasite Ventures, Pangaea Ventures Us Inc., SV Latam Capital, Y Combinator and 12 more.
How much funding has Correlia Biosystems raised?: Correlia Biosystems has disclosed $10.8M raised across 2 rounds.
Where is Correlia Biosystems headquartered?: Correlia Biosystems is headquartered in San Francisco, US.